WallStSmart

Pfizer Inc (PFE)vsSouthern Company (SO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 110% more annual revenue ($63.32B vs $30.18B). SO leads profitability with a 14.5% profit margin vs 11.8%. SO appears more attractively valued with a PEG of 2.66. SO earns a higher WallStSmart Score of 56/100 (C).

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9

SO

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 7.0Value: 3.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued
SOSignificantly Overvalued (-26.1%)

Margin of Safety

-26.1%

Fair Value

$73.33

Current Price

$91.80

$18.47 premium

UndervaluedFair: $73.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

SO3 strengths · Avg: 8.3/10
Market CapQuality
$103.49B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Operating MarginProfitability
25.8%8/10

Strong operational efficiency at 25.8%

Areas to Watch

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

SO3 concerns · Avg: 2.0/10
PEG RatioValuation
2.662/10

Expensive relative to growth rate

EPS GrowthGrowth
-0.8%2/10

Earnings declined 0.8%

Free Cash FlowQuality
$-1.72B2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bull Case : SO

The strongest argument for SO centers on Market Cap, Price/Book, Operating Margin.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Bear Case : SO

The primary concerns for SO are PEG Ratio, EPS Growth, Free Cash Flow.

Key Dynamics to Monitor

SO carries more volatility with a beta of 0.36 — expect wider price swings.

SO is growing revenue faster at 8.0% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SO scores higher overall (56/100 vs 55/100). PFE offers better value entry with a 29.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Southern Company

UTILITIES · UTILITIES - REGULATED ELECTRIC · USA

Southern Company is an American gas and electric utility holding company based in the southern United States. It is headquartered in Atlanta, Georgia, with executive offices also located in Birmingham, Alabama.

Want to dig deeper into these stocks?